Ray Dalio Bridgewater Associates
Ray Dalio is the founder of Bridgewater Associates, one of the world’s largest hedge funds, known for its unique “principles-based” culture and systematic investment approach. Dalio’s investment philosophy emphasizes diversified portfolios, risk parity, and the importance of understanding economic cycles in shaping investment decisions. He has authored several books, including “Principles: Life & Work,” in which he details his management philosophies, personal experiences, and life lessons.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$432M |
| 2 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$193M |
| 3 |
iShares MSCI South Korea ETF
EWY
|
+$95.9M |
| 4 |
Molson Coors Class B
TAP
|
+$28.7M |
| 5 |
iShares MSCI Brazil ETF
EWZ
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$172M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
+$47.9M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$21.1M |
| 4 |
Intel
INTC
|
+$20.4M |
| 5 |
JNPR
Juniper Networks
JNPR
|
+$18.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 2.75% |
| 2 | Technology | 2.62% |
| 3 | Consumer Discretionary | 2.44% |
| 4 | Financials | 1.98% |
| 5 | Healthcare | 1.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Devon Energy
DVN
$47.3B
| $5.92M | 0.06% |
129,700
-14,100
| -10% | -$623K |
|
|
SCHW
127
Charles Schwab
SCHW
$187B
| $5.76M | 0.05% |
145,900
+78,700
| +117% | +$2.81M |
|
128
Gilead Sciences
GILD
$165B
| $5.75M | 0.05% |
80,272
-235,000
| -75% | -$17.5M |
|
129
DaVita
DVA
$11.7B
| $5.67M | 0.05% |
88,244
+22,944
| +35% | +$1.43M |
|
|
CHK
130
DELISTED
Chesapeake Energy Corporation
CHK
| $5.42M | 0.05% |
3,858
+2,020
| +110% | +$2.64M |
|
|
EA
131
DELISTED
Electronic Arts
EA
| $5.29M | 0.05% |
67,200
+49,800
| +286% | +$4.01M |
|
132
Kimberly-Clark
KMB
$36.5B
| $5.27M | 0.05% |
46,200
-28,100
| -38% | -$3.26M |
|
133
Carnival Corporation Ltd
CCL
$39.7B
| $5.05M | 0.05% |
97,062
+64,833
| +201% | +$3.25M |
|
|
PARA
134
DELISTED
Paramount Global Class B
PARA
| $4.94M | 0.05% |
+77,700
| New | +$4.61M |
|
135
Royal Gold
RGLD
$19.5B
| $4.93M | 0.05% |
77,900
+22,400
| +40% | +$1.53M |
|
|
CLR
136
DELISTED
CONTINENTAL RESOURCES INC.
CLR
| $4.93M | 0.05% |
95,660
-6,600
| -6% | -$341K |
|
137
Bath & Body Works
BBWI
$4.1B
| $4.92M | 0.05% |
92,528
-95,590
| -51% | -$5.44M |
|
138
Becton Dickinson
BDX
$48.7B
| $4.89M | 0.05% |
30,253
+25,128
| +490% | +$4.17M |
|
|
CXO
139
DELISTED
CONCHO RESOURCES INC.
CXO
| $4.88M | 0.05% |
36,838
-3,700
| -9% | -$503K |
|
140
AngloGold Ashanti
AU
$48.7B
| $4.84M | 0.05% |
460,778
+118,100
| +34% | +$1.43M |
|
|
HES
141
DELISTED
Hess
HES
| $4.76M | 0.05% |
76,501
-9,599
| -11% | -$525K |
|
142
Alphabet (Google) Class A
GOOGL
$4.33T
| $4.75M | 0.05% |
120,000
-14,000
| -10% | -$560K |
|
143
Citigroup
C
$226B
| $4.64M | 0.04% |
+78,000
| New | +$4.21M |
|
144
Medtronic
MDT
$112B
| $4.44M | 0.04% |
62,300
+31,300
| +101% | +$2.46M |
|
145
Kinross Gold
KGC
$32.8B
| $4.43M | 0.04% |
1,418,950
+377,250
| +36% | +$1.32M |
|
146
Ovintiv
OVV
$16.4B
| $4.3M | 0.04% |
73,180
+21,020
| +40% | +$1.2M |
|
147
Sherwin-Williams
SHW
$89.8B
| $4.27M | 0.04% |
47,700
+8,400
| +21% | +$742K |
|
|
GGP
148
DELISTED
GGP Inc.
GGP
| $4.17M | 0.04% |
167,000
+153,400
| +1,128% | +$3.92M |
|
|
XLNX
149
DELISTED
Xilinx Inc
XLNX
| $4.1M | 0.04% |
67,918
-36,997
| -35% | -$1.99M |
|
150
Thermo Fisher Scientific
TMO
$220B
| $4.05M | 0.04% |
28,700
+18,100
| +171% | +$2.67M |
|
Similar funds
Ray Dalio's Q4 2016 Portfolio in Review
As of Q4 2016, Ray Dalio held 377 positions worth $10.5B, up 3.7% from $10.2B the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Ray Dalio deployed $653M of net new capital in Q4 2016, opening 78 new positions and adding to 101 existing holdings. Its largest new stake was UnitedHealth: 163,900 shares worth $26.2M.
By sector, the portfolio is most concentrated in Energy at 2.8% of assets, down from 2.9% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $172M trimmed.
- Ray Dalio's largest Q4 2016 buy was UnitedHealth: 163,900 shares worth $26.2M.
- Ray Dalio added most to Vanguard FTSE Emerging Markets ETF in Q4 2016, an estimated $432M increase.
- Ray Dalio's biggest Q4 2016 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $172M.
- Ray Dalio fully exited Bristol-Myers Squibb in Q4 2016, selling an estimated $21.1M.
- Ray Dalio's ten largest holdings make up 83% of its $10.5B portfolio in Q4 2016.
- Ray Dalio opened 78 new positions and closed 110 in Q4 2016.
- Ray Dalio's portfolio value rose 3.7% quarter-over-quarter to $10.5B.
Based on Bridgewater Associates's 13F filing for Q4 2016, filed 10 Feb 2017.